Edgewise Therapeutics, Inc. SEC Filings

Insider transactions by John R. Moore at Edgewise Therapeutics (EWTX): The reporting person, General Counsel John R. Moore, recorded transactions on 08/12/2025 showing both equity compensation vesting and a small sale to cover taxes. He had 5,781 RSUs vest (treated as acquired) and sold 2,098 shares in a sell-to-cover at an average price of $13.3924 (trade prices ranged $13.36–$13.49). Following these transactions, Mr. Moore directly beneficially owned 17,344 shares plus outstanding awards and options.

Compensation grants: New awards include 26,875 RSUs (vesting from 08/12/2026) and a 161,250-share stock option with a $13.39 exercise price vesting monthly from 09/12/2025 through 08/12/2035.

Edgewise Therapeutics insider activity: Behrad Derakhshan, Chief Business Officer, had RSUs vest and executed related transactions on 08/12/2025. 5,781 restricted stock units vested and were treated as acquired at $0.00. To satisfy tax withholding on those vested RSUs, 2,491 shares were sold in multiple transactions at an average price of $13.3924 (range $13.36–$13.49). Following the transactions the reporting person beneficially owned 23,645 shares of common stock directly. The filing also reports 30,000 newly granted RSUs (vesting beginning 08/12/2026) and a stock option to purchase 180,000 shares at an exercise price of $13.39 (vesting 1/48th monthly beginning 09/12/2025). The newly vested and granted awards are subject to standard service-based vesting schedules.

Edgewise Therapeutics insider transactions: R. Michael Carruthers, identified as Chief Financial Officer and reporting person, reported multiple equity transactions dated 08/12/2025. He acquired 5,781 shares of common stock and simultaneously sold 1,428 shares at an average price of $13.3924 to satisfy tax withholding from vesting restricted stock units. Following these transactions, he beneficially owned 86,162 shares of common stock. The filing also reports derivative awards: 5,781 vested restricted stock units exercisable into common shares, 26,875 newly granted restricted stock units, and a stock option to purchase 161,250 shares at an exercise price of $13.39, with vesting schedules extending through 2035. The transactions were signed by an attorney-in-fact on 08/14/2025.

Edgewise Therapeutics insider Russell Alan J reported multiple equity transactions on 08/12/2025. He acquired 5,781 shares via vesting of RSUs and sold 1,907 shares in a sell-to-cover to satisfy tax withholding at an average sale price of $13.3924 per share (individual sale prices ranged $13.36–$13.49). After these transactions he beneficially owns 23,400 shares.

The filing also shows newly granted compensation awards: 5,781 RSUs vesting in four equal annual installments beginning 08/12/2025, 28,125 RSUs vesting in four equal annual installments beginning 08/12/2026, and a stock option to purchase 168,750 shares at an exercise price of $13.39 per share exercisable beginning 09/12/2025 with a 08/12/2035 expiration. The report identifies Russell as Chief Scientific Officer and a director.

Edgewise Therapeutics insider transactions: Kevin Koch, President and CEO and director, reported multiple equity awards and a sell-to-cover on 08/12/2025. He received 17,968 RSUs that vested (or were deemed acquired) and an additional 87,500 RSUs granted with staggered vesting beginning 08/12/2026. He was also granted a 525,000-share stock option exercisable at $13.39 per share with monthly vesting starting 09/12/2025. To satisfy tax withholding, 7,972 shares were sold at an average price of $13.3924. Following these transactions, he beneficially owned 30,615 shares directly and 259,554 shares indirectly through family entities.

Insider transactions by CMO Joanne M. Donovan at Edgewise Therapeutics (EWTX): On 08/12/2025 Donovan was issued 168,750 stock options exercisable at $13.39 and 28,125 RSUs (vesting beginning 08/12/2026) and received 5,781 RSUs (vesting beginning 08/12/2034). She also acquired 5,781 shares and sold 2,862 shares in a sell-to-cover to satisfy tax withholding at an average price of $13.3924. Following these transactions she beneficially owned 25,361 common shares.

Edgewise Therapeutics, Inc. received an Amendment No. 1 to a Schedule 13G filed by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker reporting aggregate beneficial ownership of 7,305,940 shares of common stock, representing 6.9% of the 105,200,221 shares outstanding used for the calculation. The filing states the Adviser has sole investment and voting power over those shares through management agreements with two funds, Baker Brothers Life Sciences, L.P. and 667, L.P., which directly hold 6,762,577 and 543,363 shares respectively. The disclosure is presented as an amendment and certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer.

Janus Henderson Group plc filed a Schedule 13G/A reporting beneficial ownership of Edgewise Therapeutics common stock. The filing lists an aggregate holding of 5,503,349 shares, representing 5.2% of the class, with shared voting and shared dispositive power. The filing also states that certain indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) are registered investment advisers to managed portfolios, and Item 4 separately indicates JHIUS may be deemed to beneficially own 5,437,423 shares (also shown as 5.2%). The statement includes a certification that the shares are held in the ordinary course of business and not to influence control. The filing is signed by Kristin Mariani on 08/14/2025.